日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. CD22 (Suciraslimab Biosimilar) Recombinant Monoclonal Antibody

CD22 (Suciraslimab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA004900MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CD22(Suciraslimab Biosimilar Antibody)重組單克隆抗體是一種針對CD22靶點的生物制劑，主要用于生命科學(xué)研究領(lǐng)域。該抗體通過重組DNA技術(shù)制備，具有高度特異性和親和力，能夠精準(zhǔn)識別并結(jié)合B淋巴細胞表面的CD22抗原。 作為科研工具，CD22重組單克隆抗體在B細胞相關(guān)疾病機制研究中發(fā)揮重要作用，可用于探究CD22分子在B細胞發(fā)育、活化及信號轉(zhuǎn)導(dǎo)中的功能。研究人員可利用該抗體進行、分析某些實驗，以觀察B細胞的表型特征和功能狀態(tài)。 該抗體的研發(fā)為B細胞相關(guān)疾病模型的構(gòu)建提供了有力支持，有助于深入理解白血病、淋巴瘤等疾病的發(fā)病機制。在實驗室研究中，它可作為特異性探針，輔助開展靶向治療策略的前期探索，為開發(fā)新的治療方法提供實驗依據(jù)。 通過對CD22重組單克隆抗體的應(yīng)用，科研人員能夠更精準(zhǔn)地研究B細胞的生理和病理過程，推動免疫學(xué)、腫瘤學(xué)等領(lǐng)域的基礎(chǔ)研究和轉(zhuǎn)化醫(yī)學(xué)發(fā)展。該抗體嚴格按照科研級標(biāo)準(zhǔn)生產(chǎn)，確保實驗結(jié)果的可靠性和可重復(fù)性，是生命科學(xué)研究中不可或缺的工具試劑。
  • Uniprot No.：
  • 基因名：
  • 別名：
    SM03 research-grade biosimilar; SM 03 research-grade biosimilar ;CD22 antibody; SIGLEC2 antibody; B-cell receptor CD22 antibody; B-lymphocyte cell adhesion molecule antibody; BL-CAM antibody; Sialic acid-binding Ig-like lectin 2 antibody; Siglec-2 antibody; T-cell surface antigen Leu-14 antibody; CD antigen CD22 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human CD22 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
  • 基因功能參考文獻：
    1. Conjugates of these multivalent ligands with auristatin and saporin toxins are efficiently internalized via hCD22 resulting in killing of B-cell lymphoma cells PMID: 28829594
    2. This is the first time a NMR-based binding study of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma Daudi cells has been described. PMID: 27808110
    3. Here the authors structurally characterize the ectodomain of CD22 and present its crystal structure with the bound therapeutic antibody epratuzumab, which gives insights into the mechanism of inhibition of B-cell activation. PMID: 28970495
    4. hCD22 transgenic mice develop normal humoral responses in a peanut allergy oral sensitization model. Homing of B cells to Peyer's patches was partially rescued by expression of hCD22 compared with CD22(-/-) B cells, although not to wild-type levels. PMID: 28972089
    5. Diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy reduced disease burden in a non-Hodgkin lymphoma mouse model. PMID: 27524505
    6. Siglec-1 and Siglec-2 are potential biomarkers in autoimmune disease. (Review) PMID: 26752092
    7. We aimed to screen exons 9-14 of the CD22 gene, which is a mutational hot spot region in B-precursor acute lymphoblastic leukemia (pre-B ALL) patients. Nine variants, of which two novel, were found. Novel variants were in introns 10 and 13. Gly745Asp (rs10406069) variant was missense and Cys790Arg (rs79438722) variant was silent. PMID: 27486888
    8. Anti-CD22-magnetic nanoparticles-doxorubicin inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. PMID: 26379425
    9. results demonstrate that loss of high affinity CD22 ligands on GC B-cells occurs in both mice and humans through alternative mechanisms, unmasking CD22 relative to naive and memory B-cells PMID: 26507663
    10. MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. PMID: 26017478
    11. These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium. PMID: 25484043
    12. By using integrative genomics and analysing the relationships of COPD phenotypes with SNPs and gene expression in lung tissue, we identified CST3 and CD22 as potential causal genes for airflow obstruction. PMID: 25182044
    13. study detected the expression of CD22 and CD72 on B cells of myasthenia gravis, compared to multiple sclerosis patient controls and healthy controls y PMID: 23184497
    14. In the absence of functional CD22, B cells have a "hyperactivated" phenotype, CD22 dysfunction could contribute to the pathogenesis of autoimmune diseases. (Review) PMID: 23083346
    15. The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis PMID: 22986740
    16. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox has activity in relapsed/refractory hairy cell leukemia. PMID: 22355053
    17. Our study implicates the CD22DeltaE12 genetic defect in the aggressive biology of relapsed or therapy-refractory paediatric B-lineage ALL. PMID: 22017452
    18. This CD22-targeted polymer carrier may be useful for siRNA delivery to lymphoma cells. PMID: 21629223
    19. Taken together, these results suggest that negative regulation of TLR signaling of B cells is an intrinsic property of CD22. PMID: 21178327
    20. The efficacy of a ligand-targeting approach to B cell-specific depletion therapy for cancer may be the ability of CD22 to recycle and accumulate ligand-decorated cargo intracellularly, as an endocytic receptor. PMID: 21178016
    21. These striking findings implicate CD22DeltaE12 as a previously undescribed pathogenic mechanism in human B-precursor leukemia. PMID: 20841423
    22. B cell surface receptors CD20 and CD22 are significantly affected in patients with SLE, pointing to their possible involvement in the aetiopathogenesis of the disease and in the regulatory mechanisms in response to the immune disturbance. PMID: 20726320
    23. The B-cell receptor IgM was found to be a major in situ trans ligand of CD22. PMID: 20172905
    24. Data show that anti-CD22 autoantibodies were positive in 80% of TSK/+ mice and in 22% of SSc patients. PMID: 19919568
    25. The Lyn/CD22/SHP-1 pathway is important in autoimmunity. Naive and tolerant B-cells differ in their calcium signaling in response to antigenic stimulation. PMID: 11826756
    26. Disulfide bonds and the resulting 3D conformation of the CD22 molecules may have important roles in the difference of antigenicity of CD22 beta in B cells and basophils PMID: 11882357
    27. ligand-binding of CD22 influences its intracellular signaling domain and is needed for inhibition of the B cell receptor signal PMID: 11994426
    28. masking of the alpha2-6-linked sialic acid binding site of CD22 involves many cell surface sialoglycoproteins, without requiring specific ligand(s) and/or is mediated by secondary interactions with Sias on CD45 and sIgM PMID: 15240561
    29. Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells PMID: 15899772
    30. decreased CD22 expression may be associated with the activation of B cells in Bullous pemphigoid (BP), but not associated with BP-specific antibody production PMID: 17055225
    31. study showed that a synonymous SNP in CD22, c.2304C > A, was significantly associated with susceptibility to limited cutaneous systemic sclerosis PMID: 17493148
    32. The results suggest that these two siglec proteins have evolved distinct endocytic mechanisms consistent with roles in cell signaling and innate immunity. PMID: 17562860
    33. These results indicate that the alpha2-6-sialylated 6-sulfo-LacNAc determinant serves as an endogenous ligand for human CD22 and suggest the possibility that 6-GlcNAc sulfation as well as alpha2-6-sialylation may regulate Siglec-2 functions in humans. PMID: 17728258
    34. SAP is inducibly expressed in the human BJAB cells, and co-localizes and interacts with CD22. SAP binding to the inhibitory immunoreceptor CD22 regulates calcium mobilization in B cells. PMID: 19150402

    顯示更多

    收起更多

  • 亞細胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 蛋白家族：
    Immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family
  • 組織特異性：
    B-lymphocytes.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 1643

    OMIM: 107266

    KEGG: hsa:933

    STRING: 9606.ENSP00000085219

    UniGene: Hs.579691



×
生命科學(xué)計算平臺